Lisette Nixon
Papers
2
Total Citations
34
H-Index
2
About
Lisette Nixon is a leading clinical trialist whose work is reshaping treatment paradigms for HPV-positive oropharyngeal cancer, a disease whose incidence is rapidly rising. Her research centers on reducing the severe, long-term toxicities of conventional therapies without compromising the excellent survival rates seen in this patient population. Nixon is best known for her pivotal role in the PATHOS trial, a landmark phase II/III study that investigates risk-stratified, reduced-intensity adjuvant treatment following transoral surgery. This work directly addresses the critical need to de-escalate therapy for low-risk patients, a concept that has garnered significant attention (18 citations). More recently, her 2024 study comparing transoral robotic surgery (TORS) to transoral laser microsurgery (TLM) has provided crucial data on oncological outcomes, specifically highlighting TORS’s potential for superior margin clearance (16 citations). Through these high-impact contributions, Nixon is not only advancing surgical precision but also championing a future where cancer treatment is as much about preserving quality of life as it is about cure.
Research Focus
Key Achievements
Top Papers
- 1
- 2Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma16 citations · 2024